Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study

Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50％～60％of patients with DLBCL receive complete remission (CR), 30％～40％ recurrent and 10% will never be cured due to initial and secondary drug tolerance. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.

Study Overview

• Status: Unknown
• Conditions: Diffuse, Large B-Cell, Lymphoma
• Intervention / Treatment: Drug: vindesine; Drug: cyclophosphamide; Drug: Epirubicin; Drug: prednisone tablets; Drug: Rituximab; Drug: Cinobufacini Tablets

Detailed Description

Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), accounts for 30％～40％ of adults with NHL, and has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50％～60％of patients with DLBCL receive complete remission (CR), 30％～40％ recurrent and 10% will never be cured due to initial and secondary drug tolerance. The study of Tao Wu et al in domestic showed that cinobufacini combined with CHOP protocol had excellent efficacy in the treatment of NHL, with response rate reaching up to 91.7%, and the adverse reactions were mild and tolerable, whereas the response rate of single CHOP was only 62.5%. In the clinical practice of our studies, it was also found that some patients with recurrent DLBCL NHL also had shrunken or disappeared tumors and a survival time of more than 2 years after single administration of cinobufacini tablets for 3~6 months following the withdrawal of chemotherapy. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.

• Study Type: Interventional
• Enrollment (Anticipated): 316
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Shun-E Yang, Professor; Phone Number: 13669926688; Email: yangshune@medmail.com.cn

Study Locations

• China
  • Xinjiang
    • Ürümqi, Xinjiang, China, 830011
      • Recruiting
      • Cancer Hospital affiliated to Xinjiang Medical University
      • Contact: Shun-E Yang, Professor; Phone Number: 13669926688; Email: yangshune@medmail.com.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

For control and trial groups A:

Inclusion Criteria:

• Patients aged 18-70 years old;
• Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points;
• International prognostic index (IPI): ≤3 points;
• Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;
• Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);
• Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
• Patients with expected survival time>3 months;
• Patients who were well informed of this study and signed the informed consent forms.
• Patients who received administration of Rituximab.

Exclusion Criteria:

• Patients who did not conform to above criteria;
• Patients who were receiving other anti-cancer therapies;
• Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;
• Patients with double expression, double strike, trinary expression and trinary strike and CD5+;
• Patients complicated with other non-DLBCL primary malignant tumors;
• Patients who had poor compliance with their families;
• Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.
• Patients had previous history of treatment with Cinobufacini Tablets.

For control and trial groups B

Inclusion Criteria:

• Patients aged 18-70 years old;
• Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points;
• International prognostic index (IPI): ≤3 points;
• Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;
• Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);
• Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
• Patients with expected survival time>3 months;
• Patients who were well informed of this study and signed the informed consent forms.
• Patients who did not receive administration of Rituximab.

Exclusion Criteria:

• Patients who did not conform to above criteria;
• Patients who were receiving other anti-cancer therapies;
• Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;
• Patients with double expression, double strike, trinary expression and trinary strike and CD5+;
• Patients complicated with other non-DLBCL primary malignant tumors;
• Patients who had poor compliance with their families;
• Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.
• Patients had previous history of treatment with Cinobufacini Tablets.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control group A; Control group A was treated with single R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.	Drug: vindesine; 3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles; Other Names: eldisine; Drug: cyclophosphamide; 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: endoxan; Drug: Epirubicin; 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: EPI; Drug: prednisone tablets; 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles; Other Names: metacortandracin; Drug: Rituximab; 375mg/㎡,one day before CHOP protocol; Other Names: RTX
Experimental: Trial group A; Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.	Drug: vindesine; 3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles; Other Names: eldisine; Drug: cyclophosphamide; 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: endoxan; Drug: Epirubicin; 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: EPI; Drug: prednisone tablets; 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles; Other Names: metacortandracin; Drug: Rituximab; 375mg/㎡,one day before CHOP protocol; Other Names: RTX; Drug: Cinobufacini Tablets; 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities; Other Names: buformin
Active Comparator: Control group B; Control group B was treated with single CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.	Drug: vindesine; 3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles; Other Names: eldisine; Drug: cyclophosphamide; 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: endoxan; Drug: Epirubicin; 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: EPI; Drug: prednisone tablets; 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles; Other Names: metacortandracin
Experimental: Trial group B; Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.	Drug: vindesine; 3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles; Other Names: eldisine; Drug: cyclophosphamide; 750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: endoxan; Drug: Epirubicin; 60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles; Other Names: EPI; Drug: prednisone tablets; 100 mg, d1～5, 21 d as a cycle, for 4～6 cycles; Other Names: metacortandracin; Drug: Cinobufacini Tablets; 0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities; Other Names: buformin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	3-year Progression-free survival (PFS) defined as the ratio of study subjects who had disease progression or died within 3 years from the start of randomization.	3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate (ORR)	Overall response rate (ORR) that defined as the total ratio of study subjects with complete response, complete response unconfirmed and partial response after treatment. ORR=(CR+ CRu+ PR)cases/total cases×100%.	2 years
overall survival rate (OS)	3-year overall survival rate (OS) that defined as the ratio of study subjects who survived 3 years after randomization	3 years
Safety and Tolerability	Incidence of Treatment-Emergent adverse events	2 years
Relationship between synergistic effect of Cinobufacini Tablets and expression of Na+/K+-ATPase α3	Relationship between synergistic effect of Cinobufacini Tablets and expression of Na+/K+-ATPase α3	2 years

Collaborators and Investigators

• Sponsor: Xinjiang Medical University
• Investigators: Study Chair: Shun-E Yang, Professor, Cancer Hospital affiliated to Xinjiang Medical University

Study record dates

Study Major Dates

• Study Start: September 1, 2016
• Primary Completion (Anticipated): September 1, 2018
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: August 12, 2016
• First Submitted That Met QC Criteria: August 16, 2016
• First Posted (Estimate): August 18, 2016

Study Record Updates

• Last Update Posted (Actual): July 17, 2017
• Last Update Submitted That Met QC Criteria: July 12, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Keywords: Cinobufacini Tablets; CHOP protocol
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Antibiotics, Antineoplastic; Cyclophosphamide; Epirubicin; Rituximab; Prednisone; Vindesine; Buformin
• Other Study ID Numbers: XinjiangMU2016(015)V2.0

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No